Emily F. Roe

Emily F. Roe

Auto-generated profile, based on publicly available information

Emily F. Roe

Department of Biomedical Engineering, Duke University, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Science Advances
Verified
Journal Article
Open access
JCJui-Lin Chen
Jui-Lin Chen
CFChelsea N. Fries
Chelsea N. Fries
SBStella J. Berendam
Stella J. Berendam
NRNicole S. Rodgers
Nicole S. Rodgers
EREmily F. Roe
Emily F. Roe
GFGenevieve G. Fouda
Genevieve G. Fouda
To develop vaccines for certain key global pathogens such as HIV, it is crucial to elicit both neutralizing and non-neutralizing Fc-mediated effector antibody functions. Clinical evidence indicates that non-neutralizing antibody functions including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) contribute to protection against several pathogens. In this study, we demonstrated that conjugation of HIV Envelope (Env) antigen gp120 to a self-assembling nanofiber material named Q11 induced antibodies with higher breadth and functionality when compared to soluble gp120. Immunization with Q11-conjugated gp120 vaccine (gp120-Q11) demonstrated higher tier 1 neutralization, ADCP, and ADCC as compared to soluble gp120. Moreover, Q11 conjugation altered the Fc N-glycosylation profile of antigen-specific antibodies, leading to a phenotype associated with increased ADCC in animals immunized with gp120-Q11. Thus, this nanomaterial vaccine strategy can enhance non-neutralizing antibody functions possibly through modulation of immunoglobulin G Fc N-glycosylation.

30 January 2023 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
HHHelena Freire Haddad
Helena Freire Haddad
EREmily F. Roe
Emily F. Roe
JCJoel H. Collier
Joel H. Collier
Here we discuss material strategies for mucus penetration to deliver mucosal vaccines, including polymeric coatings, microneedle arrays, self-propulsion, mucus disruption, receptor targeting, and pathogen inspired methods. Created with Biorender.com .

20 November 2025 in Acta Biomaterialia
Verified
Journal Article
Closed access
EREmily F Roe
Emily F Roe
NVNicole L Votaw
Nicole L Votaw
KLKat M Lazar
Kat M Lazar
KBKaitlyn N Burke
Kaitlyn N Burke
HMHector A Miranda
Hector A Miranda
JCJoel H Collier
Joel H Collier